Adamas Pharmaceuticals (ADMS) Reaches New 12-Month Low at $9.03

Adamas Pharmaceuticals Inc (NASDAQ:ADMS)’s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $9.03 and last traded at $9.58, with a volume of 25498 shares traded. The stock had previously closed at $10.14.

ADMS has been the topic of several recent research reports. HC Wainwright set a $45.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, September 17th. ValuEngine lowered Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 28th. Mizuho restated a “buy” rating and set a $75.00 price target on shares of Adamas Pharmaceuticals in a research report on Friday, August 17th. Cowen set a $30.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $32.13.

The stock has a market capitalization of $273.63 million, a price-to-earnings ratio of -2.51 and a beta of 1.43. The company has a debt-to-equity ratio of 1.01, a current ratio of 8.95 and a quick ratio of 8.74.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.34) by $0.12. The firm had revenue of $10.61 million for the quarter, compared to analyst estimates of $10.10 million. Adamas Pharmaceuticals had a negative return on equity of 106.74% and a negative net margin of 617.27%. As a group, equities analysts expect that Adamas Pharmaceuticals Inc will post -5.23 EPS for the current year.

In other Adamas Pharmaceuticals news, CEO Gregory T. Went acquired 3,850 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were purchased at an average cost of $12.98 per share, for a total transaction of $49,973.00. Following the transaction, the chief executive officer now owns 182,610 shares in the company, valued at $2,370,277.80. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Alfred G. Merriweather sold 1,665 shares of Adamas Pharmaceuticals stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $19.18, for a total value of $31,934.70. Following the completion of the sale, the chief financial officer now owns 25,460 shares in the company, valued at $488,322.80. The disclosure for this sale can be found here. 24.60% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the company. Marshall Wace LLP bought a new stake in shares of Adamas Pharmaceuticals in the 3rd quarter worth approximately $4,316,000. Vanguard Group Inc. boosted its position in shares of Adamas Pharmaceuticals by 1.9% during the third quarter. Vanguard Group Inc. now owns 1,008,448 shares of the specialty pharmaceutical company’s stock valued at $20,189,000 after purchasing an additional 18,879 shares in the last quarter. Teachers Advisors LLC boosted its position in shares of Adamas Pharmaceuticals by 68.7% during the third quarter. Teachers Advisors LLC now owns 61,024 shares of the specialty pharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 24,859 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of Adamas Pharmaceuticals by 36.2% during the third quarter. Macquarie Group Ltd. now owns 1,785,118 shares of the specialty pharmaceutical company’s stock valued at $35,738,000 after purchasing an additional 474,808 shares in the last quarter. Finally, MetLife Investment Advisors LLC boosted its position in shares of Adamas Pharmaceuticals by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 16,709 shares of the specialty pharmaceutical company’s stock valued at $335,000 after purchasing an additional 5,940 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.chaffeybreeze.com/2018/12/08/adamas-pharmaceuticals-adms-reaches-new-12-month-low-at-9-03.html.

About Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Featured Story: Google Finance Portfolio Tips and Tricks

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply